for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celltrion, Inc.

068270.KS

Latest Trade

304,500.00KRW

Change

-4,000.00(-1.30%)

Volume

1,030,089

Today's Range

300,000.00

 - 

312,000.00

52 Week Range

133,809.53

 - 

339,500.00

As of on the Korea Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
308,500.00
Open
308,000.00
Volume
1,030,089
3M AVG Volume
28.33
Today's High
312,000.00
Today's Low
300,000.00
52 Week High
339,500.00
52 Week Low
133,809.53
Shares Out (MIL)
133.73
Market Cap (MIL)
41,089,040.00
Forward P/E
82.75
Dividend (Yield %)
--

Next Event

Q3 2020 Celltrion Inc Earnings Release

Latest Developments

More

Celltrion Inc Q2 Consolidated Operating Profit 182 Billion Won, Up 118% From Year Earlier

Celltrion Healthcare Says European Commission Grants Marketing Authorisation For Remsima SC Formulation

Celltrion Launches Human Clinical Trial Of Potential Covid-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Celltrion, Inc.

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment is mainly engaged in the development, production and sale of biosimilar products. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio and chemical drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main merchants sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs, anti-malignant tumor drugs, and other merchants. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Industry

Biotechnology & Drugs

Contact Info

23, Academy-ro, Yeonsu-gu

22014

South Korea

+82.2.16618722

https://www.celltrion.com/

Executive Leadership

Jung Jin Seo

Chairman of the Board

Woo Sung Kee

Chief Executive Officer, Director

Sin Jae Jang

Senior Vice President

Jeong Won Yoon

Senior Vice President

Sang Jun Lee

Vice President

Key Stats

2.11 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, KRW)

2017

0.9K

2018

1.0K

2019

1.1K

2020(E)

1.7K
EPS (KRW)

2017

3,035.481

2018

1,982.857

2019

2,330.000

2020(E)

3,936.432
Price To Earnings (TTM)
120.60
Price To Sales (TTM)
32.11
Price To Book (MRQ)
14.05
Price To Cash Flow (TTM)
80.87
Total Debt To Equity (MRQ)
17.23
LT Debt To Equity (MRQ)
4.99
Return on Investment (TTM)
11.23
Return on Equity (TTM)
8.92

Latest News

Latest News

South Korea's Celltrion gets UK approval for trials of COVID-19 antibody drug

South Korea's Celltrion Inc on Thursday said British regulators had given it regulatory approval for a phase I clinical trial of its experimental COVID-19 treatment drug.

South Korea approves human trials of Celltrion's COVID-19 antibody drug

South Korea on Friday approved an early stage clinical trial of Celltrion Inc's experimental COVID-19 treatment drug, making it the country's first such antibody drug to be tested on humans.

Japan's Takeda to sell some Asia-focused drugs to Celltrion for $278 million

Takeda Pharmaceutical Co Ltd <4502.T> has agreed to sell a portfolio of over-the-counter and prescription drugs marketed in the Asia Pacific region to South Korea's Celltrion Inc <068270.KS> for $278 million, it said on Thursday

Takeda to divest some Asia-focused drugs to Celltrion for about $266 mln

Takeda Pharmaceutical Co Ltd said on Thursday it will divest some over-the-counter and prescription drugs sold exclusively in Asia Pacific to South Korea's Celltrion Inc.

South Korea expects human trials of Celltrion's potential COVID-19 treatment in Europe

South Korea expects clinical trials of Celltrion Inc's experimental COVID-19 treatment to begin in Europe next month and aims to secure sizable supplies of the drug by the first half of next year, a senior health official said on Tuesday.

South Korea's Celltrion aims to start in-human COVID-19 drug trial in July

South Korea's Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated an up to 100-fold reduction in viral load of the disease in animal testing, saying it aims to start in-human clinical trials in late July.

S.Korea's Celltrion says COVID-19 drug shows 100-fold reduction in viral load

South Korea's Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated a 100-fold reduction in viral load of the disease in animal testing.

BRIEF-Celltrion Completes Neutralisation Test On Candidate Monoclonal Antibodies (Mabs) For Covid-19 Antiviral Antibody Treatment

* CELLTRION COMPLETES NEUTRALISATION TEST ON CANDIDATE MONOCLONAL ANTIBODIES (MABS) FOR COVID-19 ANTIVIRAL ANTIBODY TREATMENT

BRIEF-Celltrion Accelerates Development Of Covid-19 Antiviral Treatment And Aims To Launch Rapid Self-Testing Kit

* CELLTRION ACCELERATES DEVELOPMENT OF COVID-19 ANTIVIRAL TREATMENT AND AIMS TO LAUNCH RAPID SELF-TESTING KIT

BRIEF-Celltrion says Q4 operating profit 114 bln won, up 160% from a year ago

* CELLTRION INC: Q4 OPERATING PROFIT 114 BILLION WON, UP 160% FROM A YEAR AGO Further company coverage: (Reporting by Joyce Lee)

South Korea's Celltrion aims to set up China JV within first half of 2019: chairman

South Korean drugmaker Celltrion Inc <068270.KS> aims to set up a joint venture in China within the first half of this year, and begin selling products in the country next year, its chairman said on Sunday.

FDA approves Celltrion's biosimilar to Roche's Herceptin

The U.S. Food and Drug Administration on Friday approved South Korean drugmaker Celltrion Inc's biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.

BRIEF-Celltrion Receives FDA Approval For Herzuma

* CELLTRION INC RECEIVES FDA APPROVAL FOR HERZUMA, A HERCEPTIN BIOSIMILAR - FDA WEBSITE Source text - https://bit.ly/2vAmAqr Further company coverage:

FDA approves first biosimilar to Roche cancer drug Rituxan

Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma.

CORRECTED-U.S. FDA panel backs Celltrion copycat drug of Roche blood cancer drug

An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.

U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

Celltrion Pharm Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.

BRIEF-Celltrion signs contract worth 157.8 bln won

* Says it signs 157.8 billion won contract to provide products

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up